Clinical variables describing the total population, the low-risk cohort, and the excluded patientsa
| Total Cohort | Low-Risk Cohort | Excluded | P Valueb | |
|---|---|---|---|---|
| No. of patients (%) | 51 | 39 (76.5) | 12 (23.5) | |
| GA (weeks, days) (median) (range) | 27 4/7 (25 0/7–31 4/7) | 27 4/7 (25 5/7–30) | 28 1/7 (25 0/7–31 4/7) | NS |
| Female (No.) (%) | 29 (56.9) | 19 (48.7) | 10 (83) | <.05 |
| Weight (g) (median) (range) | 889 (517–1590) | 900 (560–1485) | 727.5 (517–1590) | NS |
| Small for GA (weight <10th percentile) (No.) (%) | 12 (23.5) | 8 (20.5) | 4 (33.3) | NS |
| Multiple births (No.) (%) | 12 (23.5) | 6 (15.4) | 6 (50) | <.05 |
| Chorioamnionitis (No.) (%) | 21 (41.2) | 16 (41.0) | 5 (41.7) | NS |
| Antenatal steroids (No.) (%) | 45 (88.2) | 34 (87.2) | 11 (91.7) | NS |
| All BPD/severe BPD (No.) (%) | 26 (51.0)/9 (17.6) | 17 (43.6)/5 (12.8) | 9 (75.0)/4 (33.3) | NS |
| Postnatal steroids (No.) (%) | 7 (13.7) | 2 (5.1) | 5 (41.7) | <.05 |
| Treated patent ductus arteriosus (No.) (%) | 25 (49.0) | 17 (43.6) | 8 (66.7) | NS |
| Early-onset sepsis (No.) (%) | 13 (25.5) | 11 (28.2) | 2 (16.7) | NS |
| Late-onset sepsis (No.) (%) | 17 (33.3) | 13 (33.3) | 4 (33.3) | NS |
| Necrotizing enterocolitis (No.) (%) | 2 (3.9) | 0 (0) | 2 (16.7) | NS |
| Treated retinopathy of prematurity (No.) (%) | 3 (5.9) | 1 (2.6) | 2 (16.7) | NS |
| Death (No.) (%) | 2 (3.9) | 0 (0) | 2 (16.7) | NS |
| 6-Mo MDI (median) (range) | 98 (74–118) | 98 (86–118) | 93 (74–102) | <.05 |
| 6-Mo PDI (median) (range) | 88 (49–111) | 88 (62–111) | 78.5 (49–88) | <.05 |
| 18-Mo MDI (median) (range) | 93 (65–127) | 93 (65–127) | 87 (79–101) | NS |
| 18-Mo PDI (median) (range) | 83 (49–103) | 84 (55–103) | 71 (49–95) | <.05 |
Note:—MDI indicates mental developmental index; PDI, psychomotor developmental index; BPD, bronchopulmonary dysplasia; NS, nonsignificant.
↵a Bronchopulmonary dysplasia: O2 supplementation for 28 days. Severe BPD: respiratory support at 36 weeks of GA. Necrotizing enterocolitis: Bell stage >2.
↵b Between low-risk cohort and excluded patients.